Friday, July 10, 2026

pharma · Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) · IgA Nephropathy (IgAN) · VERA

Vera Therapeutics

VERALOX Therapeutics is a pharma organization headquartered in Frederick, USA. It trades on NYSE under ticker VERA. Primary therapeutic focus areas include Recurrent Low-Grade Serous Ovarian Cancer (LGSOC), IgA Nephropat

4539 Metropolitan Ct, Frederick, Maryland 21704, US HQ
2018 Founded
9 Employees
Public company Type
VERA · NYSE Ticker
Company details
Status
Public
HQ
4539 Metropolitan Ct, Frederick, Maryland 21704, US
Founded
2018
Employees
9
Programs
25
Drugs
32
Patents
140
Clinical program

Capecitabine

Phase 2 · small molecule · Breast Cancer

Capecitabine for Breast Cancer is a Phase 2 program (small_molecule) at Vera Therapeutics with 1 ClinicalTrials.gov record(s).

← All Vera Therapeutics projects Phase 2 small molecule terminated

Internal code HCRN BRE18-334

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Vera Therapeutics
Phase
Phase 2
Modality
small_molecule
Indication
Breast Cancer
Status
terminated
Trials
1